AmCad BioMed Corporation (TPEX:4188)

Market Cap	848.66M
Revenue (ttm)	53.11M
Net Income (ttm)	-50.58M
Shares Out	63.33M
EPS (ttm)	-0.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,332
Average Volume	59,242
Open	13.75
Previous Close	13.40
Day's Range	13.30 - 13.75
52-Week Range	12.30 - 31.00
Beta	0.52
RSI	30.05
Earnings Date	May 9, 2025

About AmCad BioMed

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases, such as thyroid cancers, fatty liver, liver fibrosis, and obstructive sleep apnea. The company’s products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-CA, a software device for analyzing digital cytological images; AmCAD-US...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 34
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4188

Financial Performance

In 2024, AmCad BioMed's revenue was 53.11 million, a decrease of -18.62% compared to the previous year's 65.26 million. Losses were -50.58 million, 11.6% more than in 2023.